Endovascular versus medical therapy for uncomplicated type B aortic dissection: a qualitative review

Vasc Endovascular Surg. 2013 Oct;47(7):497-501. doi: 10.1177/1538574413495462. Epub 2013 Jul 12.

Abstract

Background: Uncomplicated type B dissections have been traditionally managed with antihypertensive therapy. In the endovascular era, this dictum has been revisited. This review pooled the available studies to compare the outcomes of best medical therapy (BMT) to thoracic endovascular aortic repair (TEVAR) for uncomplicated type B dissections.

Methods: A literature search was performed to identify studies on uncomplicated type B dissections managed with BMT with and without TEVAR. The primary outcome measures were mortality rates at 30 days and at 2 years following intervention.

Results: A total of 6 studies included 123 patients who underwent TEVAR/BMT, and 566 patients who had BMT alone. The mortality rates at 30 days (6.5% TEVAR/BMT vs 4.8% BMT, P = .21) and at 2 years (9.7% vs 11.9%, P = .32) were similar. Renal failure was greater in TEVAR/BMT (15.4% vs 2.1%, P < .01). Rates of surgical reintervention/intervention were similar (17.6% vs 20.1%, P = .31).

Conclusion: The TEVAR with BMT does not provide survival benefit compared to BMT alone, 2 years following uncomplicated type B aortic dissection.

Keywords: aortic dissection; endovascular repair; uncomplicated.

Publication types

  • Review

MeSH terms

  • Antihypertensive Agents / adverse effects
  • Antihypertensive Agents / therapeutic use*
  • Aortic Aneurysm, Thoracic / diagnosis
  • Aortic Aneurysm, Thoracic / mortality
  • Aortic Aneurysm, Thoracic / therapy*
  • Aortic Dissection / diagnosis
  • Aortic Dissection / mortality
  • Aortic Dissection / therapy*
  • Aortic Rupture / etiology
  • Aortography
  • Blood Vessel Prosthesis Implantation* / adverse effects
  • Blood Vessel Prosthesis Implantation* / mortality
  • Endovascular Procedures* / adverse effects
  • Endovascular Procedures* / mortality
  • Humans
  • Renal Insufficiency / etiology
  • Reoperation
  • Time Factors
  • Treatment Outcome

Substances

  • Antihypertensive Agents